GlassScriptPhysician profile
Justin Haslam
NPI 1033729512
$4,477.96
in general payments reported to CMS, 2019-2025
43 companies · $773 in 2025
The $773 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,002 · 2022: $887 · 2023: $885 · 2024: $931 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,589.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,061.75 | 2021-2025 | |
| Lilly USA, LLC | $576.59 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $270.09 | 2021-2025 | |
| Amgen INC. | $245.02 | 2022-2025 | Prolia, Evenity, Otezla |
| Glaxosmithkline, LLC. | $241.41 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $202.32 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $183.79 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $169.01 | 2021-2025 | Spravato, Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $161.08 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.28 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.66 | 2021-2025 | |
| Dynavax Technologies Corporation | $104.61 | 2021-2025 | Heplisav-B |
| Novo Nordisk INC | $96.68 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $75.38 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biohaven Pharmaceuticals, INC. | $74.94 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Haslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.